ethyl 4-trifluoromethylcyclohexane-1-carboxylate | 95233-29-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 4-trifluoromethylcyclohexane-1-carboxylate
• 英文别名: Ethyl 4-(trifluoromethyl)cyclohexanecarboxylate；Ethyl 4-(trifluoromethyl)cyclohexane-1-carboxylate
• CAS: 95233-29-7
• 化学式: C₁₀H₁₅F₃O₂
• 分子量: 224.223
• InChiKey: WZAKKJFHOHVTHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 4-trifluoromethylcyclohexane-1-carboxylate 、 4-溴-1-(溴甲基)-2-碘苯 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正庚烷 、 乙基苯 为溶剂， 反应 2.5h， 以69%的产率得到Ethyl 1-(4-bromo-2-iodobenzyl)-4-(trifluoromethyl)cyclohexanecarboxylate
  参考文献：
  名称：

  Compounds and their use as BACE Inhibitors

  摘要：

  本发明涉及式(I)的化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆。

  公开号：

  US20120165347A1
• 作为产物：
  描述：

  4-(三氟甲基)苯甲酸乙酯 在 铑 作用下， 以 乙醇 为溶剂， 60.0 ℃ 、66.66 MPa 条件下， 反应 5.0h， 以The ethyl 4-trifluoromethylcyclohexanecarboxylate (cis/trans =87%/13%) obtained的产率得到ethyl 4-trifluoromethylcyclohexane-1-carboxylate
  参考文献：
  名称：

  Trifluoromethylcyclohexane derivatives

  摘要：

  本发明涉及公式I的三氟甲基环己烷衍生物：其中R是一种具有最多18个C原子的烷基或烯基基团，该基团未被取代或被CN或至少一个卤素取代，并且其中一个或多个非相邻CH2基团可以被从以下组中选择的基团替换：-O-，-S-，-CO-，-O-CO-，-CO-O-和-C.tbd.C-，A1和A2各自独立地为：a）1,4-苯基基团，其中一个或两个CH基团可以被N替换，b）1,4-环己基基团，其中一个或两个非相邻的CH2基团可以被-O-或-S-替换，c）1,4-环己烯基，哌啶-1,4-二基，1,4-双环[2,2,2]-辛基或萘-2,6-二基基团，基团a）和b）可以被卤素原子或氰基和/或甲基基团单取代或多取代，Z1和Z2各自独立地为：-CO-O-，-O-CH-，-CH2CH2-，-CH(CN)-CH2-，-CH2-CH(CN)-，-CH.dbd.CH-，-OCH2-，-CH2O-，-CH.dbd.N-，-N.dbd.CH-，-NO.dbd.N-，-N.dbd.NO-，-N.dbd.N-或单键，并且o为0、1或2。这些化合物可用作液晶媒介物的组分，用于电光显示元件，特别是用于矩阵液晶显示器。

  公开号：

  US05209868A1

文献信息

• Process for producing 1,1-Difluorovinyl cycloaliphatic compounds
  申请人：AIR PRODUCTS AND CHEMICALS, INC.

  公开号：EP1557404A1

  公开（公告）日：2005-07-27

  This invention relates to a process for the preparation of 1,1-difluoroolefins, e.g., difluorovinyl cycloaliphatic compounds such as difluorovinylcyclohexane and derivatives by the dehydrofluorination of a trifluoromethyl-substituted cycloaliphatic compound and the resulting compositions. This method utilizes a "sterically hindered super-base" system represented by the formula M+-NRR-; where M is Na or K and R is a secondary, or tertiary alkyl or cycloalkyl group of amines for effecting dehydrofluorination of the trifluoromethyl group leading to the difluorovinyl based cycloaliphatic compounds. The sterically hindered super base can be formed by the, in situ, reaction of a sodium or potassium alkoxide, e.g., KtBuO with a lithium dialkylamide where the lithium is bonded to nitrogen atom of an amine bearing secondary or tertiary aliphatic groups.

  本发明涉及一种制备1,1-二氟烯烃的方法，例如通过三氟甲基取代的环脂化合物的脱氟氢化制备二氟乙烯基环脂化合物，例如二氟乙烯基环己烷和其衍生物，以及由此得到的组合物。该方法利用“空间位阻超碱”系统，其表示为M+-NRR-的公式；其中M为Na或K，R为二级或三级烷基或环烷基胺的烷基，用于实现三氟甲基基团的脱氟氢化，导致基于二氟乙烯基的环脂化合物。可以通过在场内反应钠或钾醇盐（例如KtBuO）与带有二级或三级脂肪族基的胺的氮原子键合的锂双烷基胺来形成空间位阻超碱。
• COMPOUNDS AND THEIR USE AS BACE INHIBITORS
  申请人：ASTRAZENECA AB

  公开号：US20160184303A1

  公开（公告）日：2016-06-30

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式（I）化合物及其制药组合物。此外，本发明还涉及用于治疗和/或预防与Aβ相关的病理学，例如唐氏综合症、β淀粉样蛋白病变（如但不限于脑淀粉样血管病变或遗传性脑出血）、与认知障碍相关的疾病（如但不限于轻度认知障碍）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、与疾病相关的神经退行性疾病（如阿尔茨海默病或痴呆症，包括混合血管性和退行性起源的痴呆、早老性痴呆、老年性痴呆和与帕金森病、进行性核上性麻痹或皮质基底节变性相关的痴呆）。
• [EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE
  申请人：ASTRAZENECA AB

  公开号：WO2012087237A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

  本发明涉及公式（I）化合物及其制药组合物。此外，本发明涉及治疗和/或预防与Αβ相关的病理学，如唐氏综合症，β-淀粉样血管病，如但不限于脑淀粉样血管病或遗传性脑出血，与认知障碍相关的疾病，如但不限于轻度认知障碍（MCI），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与阿尔茨海默病或痴呆症等疾病相关的神经退行性。包括混合血管性和退行性起源的痴呆症，早老性痴呆症，老年痴呆症和与帕金森病相关的痴呆症的治疗方法。
• Process for producing 1,1-difluorovinyl cycloaliphatic compounds
  申请人：Lal Sankar Gauri

  公开号：US20050165260A1

  公开（公告）日：2005-07-28

  This invention relates to a process for the preparation of 1,1-difluoroolefins, e.g., difluorovinyl cycloaliphatic compounds such as difluorovinylcyclohexane and derivatives by the dehydrofluorination of a trifluoromethyl-substituted cycloaliphatic compound and the resulting compositions. This method utilizes a “sterically hindered super-base” system represented by the formula M +− NRR − ; where M is Na or K and R is a secondary, or tertiary alkyl or cycloalkyl group of amines for effecting dehydrofluorination of the trifluoromethyl group leading to the difluorovinyl based cycloaliphatic compounds. The sterically hindered super base can be formed by the, in situ, reaction of a sodium or potassium alkoxide, e.g., KtBuO with a lithium dialkylamide where the lithium is bonded to nitrogen atom of an amine bearing secondary or tertiary aliphatic groups.

  本发明涉及一种制备1,1-二氟烯烃的方法，例如通过对三氟甲基取代的环脂化合物进行脱氟氢化反应，制备二氟乙烯基环脂化合物，如二氟乙烯基环己烷和其衍生物。该方法利用“空间位阻超碱”系统，该系统由公式M+−NRR−表示；其中M是Na或K，R是二级或三级胺的烷基或环烷基，用于实现对三氟甲基基团的脱氟氢化反应，从而得到基于二氟乙烯基的环脂化合物。可以通过在场内反应钠或钾醇盐，例如KtBuO和锂二烷基胺之间的反应来形成空间位阻超碱。在该反应中，锂与带有二级或三级脂肪族基团的胺的氮原子结合。
• Compounds and their use as BACE inhibitors
  申请人：Astrazeneca AB

  公开号：US08865911B2

  公开（公告）日：2014-10-21

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式（I）化合物及其药物组合物。此外，本发明涉及治疗和/或预防与Aβ相关的病理状况，如唐氏综合症、β-淀粉样物质血管病，如但不限于脑淀粉样物质血管病或遗传性脑出血，与认知障碍相关的疾病，如但不限于轻度认知障碍（MCI）、阿尔茨海默病、记忆力下降、与阿尔茨海默病相关的注意力缺陷症状，与疾病相关的神经退行性疾病，如阿尔茨海默病或痴呆症，包括混合血管性和退行性起源的痴呆、早老性痴呆、老年性痴呆和与帕金森病、进行性核上性麻痹或皮质基底节变性相关的痴呆的治疗方法。